PPBT
PURPLE BIOTECH LTD.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 13 Purple Biotech reported a significant net loss of $26.4 million for…
- Apr 27 ▲ Purple Biotech announced new preclinical data showing that its tri-s…
- Aug 14 ▼ Short interest jumps 148.4% to 26.2K
- Sep 10 Reg SHO: Reg SHO Threshold: PPBT entered the threshold list
- Sep 15 ▼ Short interest jumps 187.8% to 80.9K
- Sep 29 Reg SHO: Reg SHO Threshold: PPBT exited the threshold list
- Sep 30 ▲ Short interest falls 77.6% to 18.1K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 2 added (0 new), 0 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.420 → −$2.880 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −3.8% to 15.7K shares. 1.0 days to cover, ≈1.0% of shares.
- TrendUPTREND
21% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $9.8K |
| MORGAN STANLEY | ADD | $456.00 |
| ROYAL BANK OF CANADA | DOUBLED | Not reported |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | NEAR_EXIT | $21.6K |
| UBS Group AG | DOUBLED | $1.3K |
| MORGAN STANLEY | TRIM | $331.00 |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $13.9K |
| SIMPLEX TRADING, LLC | DOUBLED | $6.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026Price is below the lowest target. Median implies +912%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$2.88 | -$2.88–-$2.88 | -66.5% | $0.00 |
| Next Q | -$3.00 | -$3.00–-$3.00 | -19.5% | $0.00 |
| Current FY | -$5.73 | -$5.73–-$5.73 | -7.9% | $0.00 |
| Next FY | -$1.01 | -$1.01–-$1.01 | -14.8% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 3 press releases · 1 bullish · 0 bearish · 10 neutral- NEUTRAL SC 13GNov 12, 2026
Ayrton Capital LLC filed a new Schedule 13G disclosing beneficial ownership of 103,250 American…
Ayrton Capital's passive 9.99% warrant-based stake adds to existing similar positions by Intracoastal Capital and Susquehanna. Monitor for any conversion to SC 13D or exercise of warrants, which…
- NEUTRAL EFFECTNov 12, 2026
The SEC declared effective Purple Biotech Ltd.'s shelf registration statement on Form F-3 (File…
Monitor for any takedown notice or prospectus supplement indicating an actual offering. The shelf's effectiveness creates an overhang but no immediate dilution until a specific offering is announced.
- NEUTRAL SC 13G/ANov 10, 2026
Intracoastal Capital LLC and its principals filed an amended Schedule 13G disclosing beneficial…
Monitor for any future conversion of the Intracoastal warrant or changes in the blocker provision, which could signal a shift from passive to active engagement. The stake percentage has remained at…
- NEUTRAL PRESS RELEASEOct 29, 2026
Purple Biotech announced that an abstract on its lead tri-specific antibody IM1240 has been…
The oral presentation is a positive scientific validation but does not change the company's financial trajectory. Monitor for IND filing and first-in-human study initiation in 2027, which are the…
All PPBT filing & press-release reports (14)
- SC 13G reportNov 12, 2026
- EFFECT reportNov 12, 2026
- SC 13G/A reportNov 10, 2026
- PRESS-RELEASE reportOct 29, 2026
- 6-K reportOct 5, 2026
- 6-K reportSep 9, 2026
- 6-K reportSep 2, 2026
- 6-K reportAug 10, 2026
- 6-K reportAug 7, 2026
- PRESS-RELEASE reportMay 15, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 23, 2026
- PRESS-RELEASE reportMar 13, 2026
- PRESS-RELEASE reportMar 13, 2026